Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
- 1 January 2004
- Vol. 63 (1) , 120-125
- https://doi.org/10.1016/j.urology.2003.08.041
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer PatientsJournal of Clinical Endocrinology & Metabolism, 2001
- Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosisUrology, 1998
- Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegalyClinical Endocrinology, 1998
- Oral estramustine and oral etoposide for hormone-refractory prostate cancerUrology, 1997
- Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC‐3 prostate cancer cellsThe Prostate, 1995
- Phase I?II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancerCancer Chemotherapy and Pharmacology, 1995
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Treatment of patients with advanced cancer of the prostate: Phase III trial, zoladex against castration; a study of the British prostate groupJournal of Steroid Biochemistry, 1987
- Nuclear protein matrix as a target for estramustine‐induced cell deathThe Prostate, 1986